What are the common side effects of Zavicefta (ceftazidime‑avibactam) combined with aztreonam in adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Common Side Effects of Zavicefta (Ceftazidime-Avibactam) Combined with Aztreonam

The most common side effects of ceftazidime-avibactam plus aztreonam combination therapy include transaminase elevations (particularly with higher aztreonam doses), diarrhea, nausea/vomiting, rash, and local injection site reactions, with the overall safety profile being generally well-tolerated in clinical practice.

Individual Drug Side Effects

Aztreonam Side Effects (from FDA Label)

The FDA-approved aztreonam label 1 documents the following adverse reactions:

Most Common (≥1% incidence):

  • Local reactions: Phlebitis/thrombophlebitis (1.9% IV), injection site discomfort/swelling (2.4% IM)
  • Gastrointestinal: Diarrhea, nausea/vomiting (1-1.3%)
  • Dermatologic: Rash (1-1.3%)

Less Common (<1% incidence):

  • Hematologic: Neutropenia, thrombocytopenia, anemia, eosinophilia
  • Hepatic: Hepatitis, jaundice, elevated transaminases
  • Renal: Increased serum creatinine
  • Neurologic: Seizure, confusion, encephalopathy, dizziness, paresthesia
  • Hypersensitivity: Anaphylaxis, angioedema, bronchospasm (rare)
  • Other: C. difficile-associated diarrhea, fever, headache

Ceftazidime-Avibactam Side Effects

While specific FDA label data for ceftazidime-avibactam wasn't provided in the evidence, real-world data from 203 patients 2 showed:

  • Acute kidney injury: 10 patients (4.9%)
  • C. difficile infection: 3 patients (1.5%)
  • Rash: 2 patients (1.0%)
  • Gastrointestinal intolerance: 1 patient (0.5%)
  • Neutropenia: 1 patient (0.5%)

Combination-Specific Concerns

Transaminase Elevations - Critical Consideration

The most important combination-specific side effect is asymptomatic transaminase elevation, which occurs in approximately 40% of patients receiving ceftazidime-avibactam plus aztreonam 3. This finding comes from a healthy volunteer study and is dose-dependent on aztreonam:

  • High-risk dosing: Aztreonam 8 g/day (either continuous infusion or every 6 hours) - highest elevation rates
  • Lower-risk dosing: Aztreonam 6 g/day - approximately 6% elevation rate in clinical trials 3
  • Key point: Elevations were asymptomatic and resolved with drug cessation
  • Important: The transaminitis was attributed to aztreonam dosing, not the co-administration with ceftazidime-avibactam

Nephrotoxicity Risk

Nephrotoxicity remains low with this combination 4. Monte Carlo simulation modeling across varying renal function demonstrated that neurotoxicity risk (defined as ceftazidime Cmin >80 mg/L) remained low across all renal strata when appropriate dose adjustments were made 4.

Pediatric Population

In pediatric patients receiving aztreonam 1:

  • Rash: 4.3%
  • Diarrhea: 1.4%
  • Fever: 1.0%
  • Local reactions (IV): Pain (12%), erythema (2.9%), phlebitis (2.1%)
  • Neutropenia: 11.3% in children <2 years receiving 30 mg/kg every 6 hours
  • Transaminase elevations: 15-20% in children ≥2 years receiving 50 mg/kg every 6 hours

A recent case series in preterm infants 5 reported reversible adverse effects including liver function abnormalities, increased serum creatinine, hypomagnesemia, and thrombocytopenia, though one patient experienced status epilepticus (causality uncertain).

Clinical Monitoring Recommendations

Based on the evidence, monitor for:

  1. Liver function tests - particularly when using aztreonam ≥6 g/day; check baseline and weekly
  2. Renal function - baseline and every 2-3 days, especially in critically ill patients
  3. Complete blood count - monitor for neutropenia, thrombocytopenia
  4. Electrolytes - particularly magnesium levels
  5. Signs of C. difficile infection - diarrhea during or after treatment
  6. Neurologic status - particularly in patients with renal impairment or CNS infections

Important Caveats

  • The incidence of adverse events is low overall 6, with guidelines noting that "the benefit of ceftazidime-avibactam combined with aztreonam probably outweighs potential harm"
  • Most adverse effects are reversible with dose adjustment or discontinuation
  • Combination therapy did not increase adverse events compared to monotherapy in retrospective cohorts 7
  • Avoid in patients with documented β-lactam hypersensitivity
  • Use cautiously in patients with seizure disorders or significant renal impairment without appropriate dose adjustment

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.